Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). (MELYSA)
Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study.
This randomized, controlled multicenter trial will recruit patients aged 18 to 70 years with recurrent nasal polyposis requiring surgery and indication for biologic treatment according to EPOS 2020 guideline. Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment.
All study procedures will be performed in five study visits and may take approximately 30 minutes. Clinical assessments include ifferent questionnaires and nasal endoscopy. This trial includes three treatment arms.
- Combined group (In-office nasal polypectomy group with mepolizumab): This group will undergone in-office nasal polypectomy and will receive Mepolizumab.
- Medical group (mepolizumab): This group will receive Mepolizumab.
- Surgical group (In-office nasal polypectomy): This group will undergone in-office nasal polypectomy. The main advantage is that it allows comparison of mepolizumab versus surgery and surgery/mepolizumab versus surgery + mepolizumab, providing more information on the most effective therapeutic approach.
The presence of adverse effects will be assessed in each treatment arm.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and indication for biologic treatment according to the criteria of the EPOS2020 guideline.
Presence of bilateral polyps in a patient who had endoscopic sinus surgery (ESS) (except in cases where the patient is not fit for surgery) and three of the following criteria are required:
Evidence of type 2 inflammation (tissue eos> 10/hpf* or blood eos>250, OR total IgE> 100).
* Whenever possible histology from previous surgery should be reviewed to confirm if eosinophilic pathology. If the previous surgery was performed more than 2 years earlier, a blood eosinophil count is essential, as the previous biopsy data may not be relevant.
- Need for systemic corticosteroids or contraindication to systemic steroids (≥ 2 courses per yr, OR long term (>3 months)
- Significantly impaired quality of life (SNOT ≥ 40)
- Significant loss of smell (VAS).
- Diagnosis of comorbid asthma
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
Barakaldo, Spanien
- Rekrutierung
- Hospital De Cruces
-
Kontakt:
- Francisco Valcarcel
- Telefonnummer: +34946006000
- E-Mail: patxivalcarcel@gmail.com
-
Jerez de la Frontera, Spanien
- Rekrutierung
- Hospital de Jerez
-
Kontakt:
- Alfonso del cuvillo Bernal
- Telefonnummer: +34956032000
- E-Mail: dr.cuvillo@comcadiz.es
-
Madrid, Spanien
- Rekrutierung
- Hospital Puerta del Hierro
-
Kontakt:
- Antonio Martinez
- Telefonnummer: +34911916000
- E-Mail: amruizcoello@gmail.com
-
Salamanca, Spanien
- Rekrutierung
- Hospital de Salamanca
-
Kontakt:
- Maria gil
- Telefonnummer: +34923291100
- E-Mail: mgilmel@saludcastillayleon.es
-
Santander, Spanien, 39006
- Rekrutierung
- Hospital Universitario Marqués de Valdecilla
-
Kontakt:
- david lobo duro
- Telefonnummer: +34942315515
- E-Mail: david.lobo@scsalud.es
-
Seville, Spanien
- Rekrutierung
- Hospital Universitario Virgen Macarena
-
Kontakt:
- Serafín Sánchez Gómez
- Telefonnummer: +34955008000
- E-Mail: serafin.sanchez.sspa@juntadeandalucia.es
-
Valladolid, Spanien
- Rekrutierung
- Hospital de Valladolid
-
Kontakt:
- Jaime Santos
- Telefonnummer: +34983420000
- E-Mail: jsp002@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Participant 18 years of age or older
Patients with a diagnosis of CRS with polyposis according to the criteria of the EPOS2020 guideline:
Chronic rhinosinusitis with nasal polyps in adults is defined as presence of two or more symptoms, one of which should be either nasal blockage / obstruction / congestion or nasal discharge (anterior / posterior nasal drip); ± facial pain/pressure; ± reduction or loss of smell; for ≥12 weeks; and either endoscopic signs of nasal polyps, and/or CT changes: mucosal changes within the ostiomeatal complex and/or sinuses.
Patients with indication for biologic treatment according to the criteria of the EPOS2020 guideline. Presence of bilateral polyps in a patient who had ESS and three of the following criteria are required:
3.1. Evidence of type 2 inflammation (tissue eos> 10/hpf* or blood eos>250, OR total IgE> 100).
* Whenever possible histology from previous surgery should be reviewed to confirm if eosinophilic pathology. If the previous surgery was performed more than 2 years earlier, a blood eosinophil count is essential, as the previous biopsy data may not be relevant.
3.2. Need for systemic corticosteroids or contraindication to systemic steroids (≥ 2 courses per yr, OR long term (>3 months)
3.3. Significantly impaired quality of life (SNOT ≥ 40)
3.4. Significant loss of smell (≥7 VAS)
3.5. Diagnosis of comorbid asthma
- Basal eosinophil count (BEC) ≥300 cells/µL for surgical naïve patients- or for those who have had surgery and have recurrence . The result of a previous analysis would be valid if it was obtained in a period of time not exceeding one year
- Patients have been informed and signed consent to participate in the study.
Exclusion Criteria:
- Any serious or uncontrolled systemic or psychiatric illness that prevents a correct cognitive or endoscopic assessment or does not advise participation in the study.
- Unilateral localized secondary CRS (odontogenic, fungal ball, tumor).
- Bilateral diffuse secondary CRS (cystic fibrosis; eosinophilic granulomatosis with polyangiitis-S. de Churg-Strauss-; granulomatosis with polyangiitis-S de Wegener-; primary ciliary dyskinesia; selective immunodeficiencies.
- Pregnancy/ breast feeding.
- Hypersensitivity to mepolizumab or its excipients.
- Patients unable to complete the questionnaire or follow prescribed treatment.
- Patients who are participating in another clinical trial related to polyposis or asthma.
- Previously documented failure with IL-5/IL-5 receptor biologics
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: surgical arm
This group of patients will undergo nasal polypectomy in the office and will not receive mepolizumab treatment.
|
polypectomy in the office and will not receive mepolizumab treatment.
|
|
Experimental: medical arm
This group of patients will not undergo in-office nasal polypectomy and will start treatment with mepolizumab directly after randomization.
|
will not undergo in-office nasal polypectomy and will start treatment with mepolizumab directly after randomization.
|
|
Experimental: combined arm
This group of patients will undergo in-office nasal polypectomy before starting treatment with mepolizumab.
Mepolizumab treatment will be administered at the surgical procedure visit or within 48 hours after the polypectomy.
|
in-office nasal polypectomy before starting treatment with mepolizumab.
Mepolizumab treatment will be administered at the surgical procedure visit or within 48 hours after the polypectomy.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
the efficacy of mepolizumab+polypectomy compared to mepolizumab or polypectomy, using the change from baseline in sinonasal outcome test (SNOT-22) total score at week 52.
Zeitfenster: 12 moths
|
SNOT-22 total score ranges from 0 to 110, with higher scores indicating worse quality of life/more severe symptoms.
|
12 moths
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in nasal polyposis severity VAS score at V1, V6, V12.
Zeitfenster: 1 month, 6 months and 12 months
|
VAS score ranges from 0 to 100, with higher scores indicating greater symptom severity.
|
1 month, 6 months and 12 months
|
|
Change in endoscopic nasal polyp score at V1, V6, V12
Zeitfenster: 1 month, 6 months and 12 months
|
1 month, 6 months and 12 months
|
|
|
Improvement in individual VAS symptoms (rhinorrhea, mucus in throat, nasal blockage, and sense of smell), patient-reported outcomes at V1, V6, V12
Zeitfenster: 1 month, 6 months and 12 months
|
1 month, 6 months and 12 months
|
|
|
Number of patients no longer requiring rescue systemic corticosteroid treatment throughout the first year after the first month of starting the study
Zeitfenster: 12 months
|
12 months
|
|
|
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Related to Mepolizumab and/or In-office Nasal Polypectomy
Zeitfenster: 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months
|
Adverse events collected at each study visit and classified as serious or non-serious per protocol definitions, and by causal relationship to treatment (unrelated, possible, probable) as assessed by the investigator.
|
1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months
|
|
Change from baseline in sinonasal outcome test (SNOT-22) total score at weeks 4 and 24
Zeitfenster: 1 month and 12 months
|
1 month and 12 months
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- MELYSA
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .